Form 4: NHC President & COO Exercises Stock Options
Insider Transaction Report
National Healthcare Corp's President & COO, Robert Michael Ussery, exercised stock options and sold shares to cover taxes, increasing his direct beneficial ownership.
Summary
- Robert Michael Ussery, President & COO of National Healthcare Corp (NHC), reported transactions on November 11, 2025, involving the exercise of stock options and subsequent share dispositions.
- Ussery exercised 4,500 stock options at an exercise price of $53.94 per share.
- He also exercised an additional 4,500 stock options at an exercise price of $94.1 per share.
- To cover the exercise price and withholding tax obligations, Ussery disposed of 1,705 shares at $132.2 per share.
- An additional 3,720 shares were disposed of at $132.2 per share for the same purpose.
- Following these transactions, Ussery directly beneficially owns 161,523 shares of NHC Common Stock.
- The transactions were executed pursuant to a Rule 10b5-1(c) plan.
- The stock option grants and exercises are exempt from Section 16(b) under Rule 16b-3(d).
Sentiment
Score: 7
Explanation: The exercise of stock options by a key executive (President & COO) generally signals confidence in the company's future performance. While some shares were sold to cover taxes and exercise costs, the net effect is an increase in the executive's direct beneficial ownership, which is typically viewed positively by investors. The use of a Rule 10b5-1 plan also indicates pre-planned, rather than opportunistic, transactions.
Positives
- President & COO Robert Michael Ussery exercised a total of 9,000 stock options, signaling confidence in the company's future performance.
- There was a net increase in Ussery's direct beneficial ownership of 3,575 shares (9,000 shares acquired minus 5,425 shares disposed for tax/exercise costs).
- The transactions were conducted under a pre-arranged Rule 10b5-1(c) plan, indicating a systematic and pre-scheduled approach to managing equity rather than opportunistic trading.
Negatives
- A total of 5,425 shares were disposed of at $132.2 per share to cover the exercise price and withholding tax obligations, which represents a reduction in the gross number of shares acquired through option exercise.
Risks
- No specific risks are detailed in this Form 4 filing, as it primarily reports insider transactions rather than operational or financial risks.
Future Outlook
Not applicable. This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions and does not provide information to analyze broader industry trends or competitors. It reflects an executive's personal equity management within the healthcare sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan | The stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan. | Not specified for the plan itself, but grants occurred on 03/08/2023 and 03/05/2024. | Reinforces the company's framework for executive compensation and equity incentives. |
| Trading Plan | Transactions were made pursuant to a Rule 10b5-1(c) plan. | Not specified for the plan's establishment date, but transactions occurred on 11/11/2025. | Provides an affirmative defense against insider trading allegations, enhancing transparency and investor confidence in the legitimacy of insider trades. |
Stakeholder Impact
- Shareholders may view the executive's option exercise and increased beneficial ownership as a positive signal of management's confidence in the company's long-term prospects. The use of a 10b5-1 plan can also reassure investors about the legitimacy of the transactions.
Key Dates
| Date | Description |
|---|---|
| 03/08/2023 | Grant date for 4,500 stock options with an exercise price of $53.94. |
| 03/05/2024 | Grant date for 4,500 stock options with an exercise price of $94.1. |
| 03/08/2024 | Date exercisable for 4,500 stock options with an exercise price of $53.94. |
| 03/05/2025 | Date exercisable for 4,500 stock options with an exercise price of $94.1. |
| 11/11/2025 | Transaction date for the exercise of stock options and disposition of shares. |
| 11/13/2025 | Signature date of the reporting person. |
| 02/24/2026 | Date exercisable for 15,000 stock options with an exercise price of $90.62. |
| 03/08/2028 | Expiration date for 4,500 stock options with an exercise price of $53.94. |
| 03/05/2029 | Expiration date for 4,500 stock options with an exercise price of $94.1. |
| 02/24/2030 | Expiration date for 15,000 stock options with an exercise price of $90.62. |
Keywords
National Healthcare Corp, NHC, Robert Michael Ussery, Form 4, Insider Trading, Stock Options, Beneficial Ownership, Executive Compensation, Rule 10b5-1, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.